[go: up one dir, main page]

LT2996473T - Kompozicijos ir būdai, skirti aktyvuoti nuo "interferono geno stimuliatoriaus" priklausomą signalinį kelią - Google Patents

Kompozicijos ir būdai, skirti aktyvuoti nuo "interferono geno stimuliatoriaus" priklausomą signalinį kelią

Info

Publication number
LT2996473T
LT2996473T LT14800848T LT14800848T LT2996473T LT 2996473 T LT2996473 T LT 2996473T LT 14800848 T LT14800848 T LT 14800848T LT 14800848 T LT14800848 T LT 14800848T LT 2996473 T LT2996473 T LT 2996473T
Authority
LT
Lithuania
Prior art keywords
geno
stimulator
interferon
activating
compositions
Prior art date
Application number
LT14800848T
Other languages
English (en)
Inventor
Thomas Dubensky
David Kanne
Meredith Leong
Laura Glickman
Russell Vance
Edward Lemmens
Original Assignee
Aduro Biotech Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51934006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2996473(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aduro Biotech Inc, Univ California filed Critical Aduro Biotech Inc
Publication of LT2996473T publication Critical patent/LT2996473T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Saccharide Compounds (AREA)
LT14800848T 2013-05-18 2014-05-18 Kompozicijos ir būdai, skirti aktyvuoti nuo "interferono geno stimuliatoriaus" priklausomą signalinį kelią LT2996473T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361825005P 2013-05-18 2013-05-18
US201361902125P 2013-11-08 2013-11-08
PCT/US2014/038525 WO2014189805A1 (en) 2013-05-18 2014-05-18 Compositions and methods for activating "stimulator of interferon gene"-dependent signalling

Publications (1)

Publication Number Publication Date
LT2996473T true LT2996473T (lt) 2019-12-10

Family

ID=51934006

Family Applications (1)

Application Number Title Priority Date Filing Date
LT14800848T LT2996473T (lt) 2013-05-18 2014-05-18 Kompozicijos ir būdai, skirti aktyvuoti nuo "interferono geno stimuliatoriaus" priklausomą signalinį kelią

Country Status (37)

Country Link
US (3) US9724408B2 (lt)
EP (2) EP3653637A1 (lt)
JP (1) JP6453855B2 (lt)
KR (1) KR20160009039A (lt)
CN (1) CN105228450B (lt)
AP (1) AP2015008700A0 (lt)
AU (1) AU2014268836B2 (lt)
BR (1) BR112015028341A2 (lt)
CA (1) CA2904536A1 (lt)
CL (1) CL2015002522A1 (lt)
CR (1) CR20150616A (lt)
CU (1) CU24377B1 (lt)
CY (1) CY1122274T1 (lt)
DK (1) DK2996473T3 (lt)
DO (1) DOP2015000281A (lt)
EC (1) ECSP15052938A (lt)
ES (1) ES2754269T3 (lt)
GT (1) GT201500326A (lt)
HR (1) HRP20191972T1 (lt)
HU (1) HUE046942T2 (lt)
IL (1) IL242359B (lt)
LT (1) LT2996473T (lt)
ME (1) ME03586B (lt)
MX (1) MX354057B (lt)
MY (1) MY175308A (lt)
NI (1) NI201500162A (lt)
PE (1) PE20160080A1 (lt)
PH (1) PH12015502438B1 (lt)
PL (1) PL2996473T3 (lt)
PT (1) PT2996473T (lt)
RS (1) RS59500B1 (lt)
SA (1) SA515370123B1 (lt)
SG (1) SG11201508273RA (lt)
SI (1) SI2996473T1 (lt)
SM (1) SMT201900635T1 (lt)
SV (1) SV2015005107A (lt)
WO (1) WO2014189805A1 (lt)

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
CN107648668B (zh) 2010-10-06 2021-06-18 哈佛学院董事会 用于基于材料的细胞疗法的可注射的成孔水凝胶
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
AU2013271375B2 (en) 2012-06-08 2018-03-22 Aduro Biotech, Inc. Compositions and methods for cancer immunotherapy
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
ES2822584T3 (es) 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2015017652A1 (en) * 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP3071209A4 (en) * 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
JP6462006B2 (ja) 2014-06-04 2019-01-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingのモジュレーターとしての環式ジヌクレオチド
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
US11058758B2 (en) * 2014-11-20 2021-07-13 National Institutes Of Biomedical Innovation, Health And Nutrition TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same
CN107148424B (zh) * 2014-12-16 2021-01-08 凯拉治疗股份公司 用于诱导细胞因子的环状二核苷酸
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3250250A4 (en) * 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
WO2016130616A1 (en) 2015-02-11 2016-08-18 The Johns Hopkins University Bacteria over-expressing c-di-amp and therapeutic methods
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN106692967A (zh) * 2015-08-12 2017-05-24 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP联合PD1的抗体(Nivolumab)在制备抗肿瘤药物中的应用
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EA034786B1 (ru) * 2015-08-13 2020-03-20 Мерк Шарп И Доум Корп. Циклические динуклеотидные соединения в качестве агонистов sting
CN106540255A (zh) * 2015-09-18 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用
EP3368072A4 (en) 2015-10-28 2019-07-03 Aduro BioTech, Inc. COMPOSITIONS AND METHOD FOR ACTIVATING SIGNALING DEPENDENT ON THE STIMULATOR OF THE INTERFERON GENE
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
RU2020113165A (ru) * 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
US20180369268A1 (en) * 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
SMT202500412T1 (it) 2016-01-11 2025-11-10 Innate Tumor Immunity Inc Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro
BR112018014150A2 (en) 2016-01-11 2018-12-11 Novartis Ag immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
CN106544319A (zh) * 2016-01-24 2017-03-29 聊城市奥润生物医药科技有限公司 一种用于刺激树突状细胞成熟的组合物及其用于刺激树突状细胞成熟的方法
EP3411475B1 (en) 2016-02-06 2025-08-27 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
NZ746112A (en) * 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
CN106540256A (zh) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
MX2018012249A (es) 2016-04-19 2019-02-07 Innate Tumor Immunity Inc Moduladores de nlpr3.
US10533007B2 (en) 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
US10696985B1 (en) 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018009652A1 (en) * 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
AU2017293781B2 (en) * 2016-07-06 2022-12-22 Invox Pharma Limited Compounds, compositions, and methods for the treatment of disease
CN115537372A (zh) 2016-07-13 2022-12-30 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
EP3493842A4 (en) 2016-08-02 2020-07-29 President and Fellows of Harvard College BIOMATERIALS TO MODULATE IMMUNE RESPONSES
CA3069780A1 (en) 2016-08-09 2018-02-15 Aarhus Universitet Modulation of ifi16 and sting activity
KR102497742B1 (ko) 2016-08-30 2023-02-10 다나-파버 캔서 인스티튜트 인크. 약물 전달 조성물 및 그의 용도
WO2018053508A1 (en) 2016-09-19 2018-03-22 The University Of North Carolina At Chapel Hill Methods and compositions for inducing an immune response
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
TN2020000158A1 (en) 2016-10-04 2022-04-04 Merck Sharp & Dohme BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
EP3523314A1 (de) 2016-10-07 2019-08-14 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
CN110381996A (zh) * 2016-10-11 2019-10-25 艾伯塔大学理事会 包含环状二核苷酸或古细菌脂质体作为佐剂的丙型肝炎病毒免疫原性组合物及其使用方法
JOP20170188A1 (ar) * 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
JOP20170192A1 (ar) * 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
JP2018090562A (ja) * 2016-12-01 2018-06-14 武田薬品工業株式会社 環状ジヌクレオチド
CA3047394A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
CA3047113A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
WO2018138684A1 (en) 2017-01-27 2018-08-02 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
AU2018212788A1 (en) 2017-01-27 2019-07-25 Janssen Biotech, Inc. Cyclic dinucleotides as STING agonists
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
JP2018131427A (ja) * 2017-02-17 2018-08-23 国立研究開発法人理化学研究所 免疫細胞の制御技術
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
EP3585379A4 (en) 2017-02-21 2020-12-02 Board of Regents, The University of Texas System CYCLIC DINUCLEOTIDES USED AS AGONISTS OF THE INTERFERON-DEPENDENT SIGNALING STIMULATOR
CN106727331B (zh) * 2017-03-13 2022-02-01 杭州星鳌生物科技有限公司 免疫脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
SG11201908530QA (en) 2017-03-20 2019-10-30 Genocea Biosciences Inc Treatment methods
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
SG11201908813QA (en) 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
AU2018252193B2 (en) 2017-04-14 2024-12-12 Tallac Therapeutics, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP3621624B1 (en) * 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
CN108853144A (zh) * 2017-05-16 2018-11-23 科济生物医药(上海)有限公司 Toll样受体激动剂与免疫效应细胞的联用
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3641812A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
SG11202000248UA (en) 2017-07-14 2020-02-27 Innate Tumor Immunity Inc Nlrp3 modulators
EP3431484A1 (en) * 2017-07-21 2019-01-23 Ludwig-Maximilians-Universität München A fluorescent cyclic dinucleotide and its use in methods of identifying substances having an ability to modulate the cgas/sting pathway
CN110997691B (zh) * 2017-07-28 2023-11-07 百时美施贵宝公司 作为抗癌剂的环二核苷酸
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
RU2020109328A (ru) 2017-08-04 2021-09-06 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
CN111263767B (zh) 2017-08-30 2023-07-18 北京轩义医药科技有限公司 作为干扰素基因调节剂的刺激剂的环状二核苷酸
US10947263B2 (en) * 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CA3074232A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
EP3676279B1 (en) * 2017-08-31 2021-12-01 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
PL3678668T3 (pl) 2017-09-08 2024-06-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
BR112020006780A2 (pt) 2017-10-05 2020-10-06 Glaxosmithkline Intellectual Property Development Limited moduladores do estimulador de genes do interferon (sting)
JP2020536106A (ja) 2017-10-05 2020-12-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Hivの処置に有用なインターフェロン遺伝子の刺激物質(sting)の調節物質
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
CN111566119A (zh) 2017-11-10 2020-08-21 武田药品工业有限公司 Sting调节剂化合物以及制备和使用方法
EA038805B1 (ru) * 2017-11-21 2021-10-21 Такеда Фармасьютикал Компани Лимитед Циклические динуклеотиды в качестве агонистов sting (стимулятор генов интерферона)
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
WO2019104353A1 (en) * 2017-11-27 2019-05-31 Children's Medical Center Corporation Stimulator of interferon genes (sting) ligands and uses thereof
AU2018386222B2 (en) * 2017-12-15 2023-04-20 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
TWI818943B (zh) * 2018-01-04 2023-10-21 中央研究院 用於增加療效之可與細胞結合的免疫佐劑
WO2019147509A1 (en) * 2018-01-26 2019-08-01 The Regents Of The University Of California Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis
WO2019150310A1 (en) 2018-02-02 2019-08-08 Novartis Ag Combination of sting agonist and il-15/il15-ra for the treatment of cancer
CA3090659A1 (en) * 2018-02-06 2019-08-15 Stipe Therapeutics Aps Modulation of p62 and sting activity
US12220462B1 (en) 2018-02-13 2025-02-11 Abionyx Pharma Sa Complexes for delivery of cyclic dinucleotides
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
CN110272462B (zh) * 2018-03-15 2023-03-10 南开大学 制备化合物的方法
EP3768310A1 (en) 2018-03-23 2021-01-27 Codiak BioSciences, Inc. Extracellular vesicles comprising sting-agonist
JP2021519279A (ja) 2018-03-27 2021-08-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾環式ジヌクレオチド化合物
JP2021519270A (ja) 2018-03-27 2021-08-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 2−アザ−ヒポキサンチンまたは6h−ピラゾロ[1,5−d][1,2,4]トリアジン−7−オンをstingアゴニストとして含む環式ジヌクレオチド化合物
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
WO2019195124A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Benzothiophenes and related compounds as sting agonists
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
WO2019209896A1 (en) 2018-04-25 2019-10-31 Innate Tumor Immunity, Inc. Nlrp3 modulators
CN108310378A (zh) * 2018-04-28 2018-07-24 杭州星鳌生物科技有限公司 一类新型免疫联体抗肿瘤创新药物的制备及其应用
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CN112512531B (zh) 2018-06-01 2024-04-09 卫材R&D管理有限公司 用于膀胱癌的治疗的方法
EP3810151B1 (en) 2018-06-20 2025-08-06 Yale University Rig-i agonists and treatments using same
EP3818044A1 (en) 2018-07-03 2021-05-12 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2020010092A1 (en) 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CA3106110A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CN118147029A (zh) 2018-07-11 2024-06-07 阿克蒂姆治疗有限公司 工程化的免疫刺激性细菌菌株及其用途
SG11202101486RA (en) 2018-08-16 2021-03-30 Innate Tumor Immunity Inc Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
MX2020013322A (es) 2018-08-16 2021-02-22 Eisai R&D Man Co Ltd Sales de compuestos y cristales de los mismos.
EP3837014B1 (en) 2018-08-16 2022-10-19 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
JP7433291B2 (ja) 2018-08-16 2024-02-19 イネイト・テューマー・イミュニティ・インコーポレイテッド イミダゾ[4,5-c]キノリン誘導体のNLRP3モジュレーター
KR102567590B1 (ko) 2018-09-06 2023-08-17 다이이찌 산쿄 가부시키가이샤 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
US20220031825A1 (en) * 2018-09-17 2022-02-03 Quratis Inc. Immunological adjuvant and vaccine composition including sting agonist
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
KR102755652B1 (ko) 2018-09-21 2025-01-21 상하이 드 노보 파마테크 컴퍼니 리미티드 고리형 디뉴클레오티드 유사체, 이의 약학 조성물 및 용도
CN113272015A (zh) 2018-10-29 2021-08-17 健诺西生物科学公司 治疗方法
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
AU2019371206A1 (en) 2018-10-29 2021-05-27 Venenum Biodesign, LLC Novel sting agonists
US20220008346A1 (en) 2018-10-30 2022-01-13 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
JP2022509929A (ja) 2018-10-31 2022-01-25 ノバルティス アーゲー Stingアゴニストを含むdc-sign抗体コンジュゲート
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
EP3891165A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
EP3891166A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
WO2020117625A1 (en) * 2018-12-07 2020-06-11 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
CN111423483B (zh) * 2019-01-10 2025-01-17 英诺生物制药(深圳)有限公司 环二核苷酸前药分子及其制备方法和应用
WO2020150114A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Heterocyclic nlrp3 modulators, for use in the treatment of cancer
EP3911641A1 (en) 2019-01-14 2021-11-24 Innate Tumor Immunity, Inc. Nlrp3 modulators
WO2020150116A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Nlrp3 modulators
EP3911416B1 (en) 2019-01-14 2024-06-12 Innate Tumor Immunity, Inc. Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US10998091B2 (en) 2019-02-07 2021-05-04 Sandeep Patil Systems for monitoring compliance with a patch dosage regimen and methods of using the same
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
DK3934757T3 (da) * 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
AU2020231115B2 (en) * 2019-03-07 2025-02-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
MY205586A (en) 2019-03-18 2024-10-28 Janssen Pharmaceuticals Inc Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
US20240108747A1 (en) 2019-03-21 2024-04-04 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
US12233356B2 (en) 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles
SG11202109702QA (en) 2019-03-21 2021-10-28 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
EP3946324B1 (en) 2019-04-04 2025-07-30 Merck Sharp & Dohme LLC Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP7621974B2 (ja) * 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Stingモジュレータとしての修飾環状ジヌクレオシド化合物
IL287938B2 (en) 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody-drug conjugates
WO2020243519A1 (en) 2019-05-29 2020-12-03 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20230181758A1 (en) 2019-07-03 2023-06-15 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
WO2021003445A1 (en) 2019-07-03 2021-01-07 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
AU2020310853A1 (en) 2019-07-05 2022-01-27 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
TW202114710A (zh) 2019-07-25 2021-04-16 英屬開曼群島商百濟神州有限公司 作為sting促效劑之環狀二核苷酸
KR20220056176A (ko) 2019-08-02 2022-05-04 메르사나 테라퓨틱스, 인코포레이티드 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP3785719A1 (en) * 2019-08-28 2021-03-03 Helmholtz-Zentrum für Infektionsforschung GmbH New use of cyclic dinucleotides
EP4034081A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Extracellular vesicle compositions
WO2021062290A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
US20230241089A1 (en) 2019-09-25 2023-08-03 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
JP2022551420A (ja) 2019-09-25 2022-12-09 コディアック バイオサイエンシーズ, インコーポレイテッド 腫瘍を治療するためのil-12提示エクソソームとstingアゴニスト含有エクソソームとの併用
AU2020358862A1 (en) 2019-10-02 2022-04-14 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
EP4069683A1 (en) 2019-12-06 2022-10-12 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
KR20220127848A (ko) 2020-01-10 2022-09-20 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
WO2021144369A1 (en) 2020-01-16 2021-07-22 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
BR112022015283A2 (pt) 2020-03-06 2022-09-20 Daiichi Sankyo Co Ltd Conjugado anticorpo-fármaco incluindo derivados de dinucleotídeos cíclicos
EP4117717A1 (en) 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Extracellular vesicles for treating neurological disorders
EP4121450A2 (en) 2020-03-20 2023-01-25 Codiak BioSciences, Inc. Extracellular vesicles for therapy
MY210304A (en) 2020-04-02 2025-09-10 Mersana Therapeutics Inc Antibody drug conjugates comprising sting agonists
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
US11857618B2 (en) 2020-04-17 2024-01-02 Emory University Boosting immunogenicity of vaccines using saponins and agonists of the intracellular stimulator of interferon genes pathway
CN115835856A (zh) 2020-05-13 2023-03-21 麻省理工学院 聚合物微装置的组合物以及其在癌症免疫疗法中的用途
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2022032191A1 (en) 2020-08-07 2022-02-10 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
KR20230061360A (ko) 2020-09-02 2023-05-08 다이이찌 산쿄 가부시키가이샤 신규 엔도-β-N-아세틸글루코사미니다아제
CA3191593A1 (en) 2020-09-08 2022-03-17 Jinming Gao Polyvalent sting activating compositions and uses thereof
KR20230043157A (ko) 2020-09-17 2023-03-30 얀센 파마슈티칼즈, 인코포레이티드 다가 백신 조성물 및 이의 용도
EP4216993A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066934A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022079175A1 (en) 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
EP3984535A1 (en) 2020-10-16 2022-04-20 Albert-Ludwigs-Universität Freiburg Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
AU2021363267A1 (en) 2020-10-20 2023-06-22 Tyligand Bioscience (Shanghai) Limited Multifunctional cyclic dinucleotide and use thereof
CN115160392A (zh) * 2020-10-20 2022-10-11 泰励生物科技(上海)有限公司 多功能环二核苷酸及其用途
JP2023548310A (ja) 2020-10-30 2023-11-16 アバクタ・ライフ・サイエンシーズ・リミテッド Fap活性化血清半減期延長型治療用コンジュゲート
EP4240488A1 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antibody drug conjugates
JP2023554396A (ja) 2020-12-17 2023-12-27 トラスティーズ オブ タフツ カレッジ Fap活性化ラジオセラノスティクスおよび関連する使用
CN117529475A (zh) 2021-01-08 2024-02-06 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的含脲或类似物的杂双环化合物及其化合物
TW202241929A (zh) 2021-01-12 2022-11-01 美商詹森藥物公司 FimH突變體、其組成物及其用途
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體-免疫賦活化劑共軛物之新穎製造方法
CA3215752A1 (en) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
JP2024514707A (ja) 2021-04-20 2024-04-02 アンスティテュ・クリー 免疫療法における使用のための組成物及び方法
WO2022223622A1 (en) 2021-04-20 2022-10-27 Institut Curie Compositions and methods for use in immunotherapy
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
US20220313724A1 (en) * 2021-05-17 2022-10-06 Highlight Therapeutics, S.L. Compositions for intratumoral administration and related methods
EP4359544A4 (en) * 2021-06-24 2025-08-13 Univ Miami STING-DEPENDENT ADJUVANTS
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
CN114106140A (zh) * 2021-11-23 2022-03-01 哈尔滨医科大学附属肿瘤医院 一种表达特定sting异构体、细胞系、制备方法、用途
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
TW202346322A (zh) 2022-03-02 2023-12-01 日商第一三共股份有限公司 含Fc分子之製造方法
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
EP4582106A1 (en) 2022-08-29 2025-07-09 Daiichi Sankyo Company, Limited Antibody-drug conjugate including mutant fc region
WO2024211577A1 (en) 2023-04-05 2024-10-10 Massachusetts Institute Of Technology Hybrid polymeric systems and methods of use thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US6183121B1 (en) 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
AU741602B2 (en) 1998-02-02 2001-12-06 Johns Hopkins University School Of Medicine, The A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
EP1153931B1 (en) 1999-02-15 2005-07-20 Nippon Shinyaku Co., Ltd. Shortened-chain polynucleotides and process for the preparation thereof
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
JP4638098B2 (ja) 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
US20020150588A1 (en) 2000-09-21 2002-10-17 Allison James P. SPAS-1 cancer antigen
JP2004511527A (ja) 2000-10-18 2004-04-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US7279883B2 (en) 2001-01-23 2007-10-09 Lydia L. Sohn Particle analyzer and methods for use thereof
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
ZA200500963B (en) * 2002-08-19 2006-10-25 Coley Pharm Group Inc Immunostimulatory nucleic acids
WO2005030186A2 (en) 2003-07-28 2005-04-07 Univ Maryland Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
JP2007509067A (ja) 2003-10-15 2007-04-12 メディミューン,インコーポレーテッド リステリアに基づくEphA2ワクチン
EP1677765A1 (en) 2003-10-24 2006-07-12 Alza Corporation Preparation of lipid particles
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
CA2560058C (en) * 2004-03-15 2011-10-18 David K.R. Karaolis A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
EP1888790A2 (en) 2005-05-06 2008-02-20 The Regents of the University of California Microfluidic system for identifying or sizing individual particles passing through a channel
US20070059683A1 (en) 2005-09-15 2007-03-15 Tom Barber Veterinary diagnostic system
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
JP5623016B2 (ja) 2005-12-01 2014-11-12 プロネイ・セラピューティクス・インコーポレイテッドPronaitherapeutics, Inc. 癌治療法およびそれに用いる医薬組成物
US8304529B2 (en) 2006-07-28 2012-11-06 Life Technologies Corporation Dinucleotide MRNA cap analogs
AU2007292302A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
WO2010017248A2 (en) 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
US8765171B2 (en) 2009-03-09 2014-07-01 The Regents Of The University Of California Methods and compositions for liposomal formulation of antigens and uses thereof
US8414630B2 (en) 2009-03-10 2013-04-09 Marc Evan Richelsoph Active bone screw
LT2437753T (lt) 2009-06-05 2016-12-12 Infectious Disease Research Institute Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
WO2011003025A1 (en) 2009-07-01 2011-01-06 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
US8771933B2 (en) 2009-10-06 2014-07-08 Massachusetts Institute Of Technology Continuous-flow deformability-based cell separation
WO2011119492A2 (en) 2010-03-22 2011-09-29 Massachusetts Institute Of Technology Methods and compositions related to the measurement of material properties
CN102199183B (zh) 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
WO2011136828A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
ES2684684T3 (es) 2010-11-17 2018-10-04 Aduro Biotech, Inc. Métodos y composiciones para inducir una respuesta inmune al EGFRVIII
US9061048B2 (en) 2010-12-15 2015-06-23 The Regents Of The University Of California Cyclic di-AMP induction of type I interferon
AU2011349278C1 (en) 2010-12-22 2017-01-19 Alios Biopharma, Inc. Cyclic nucleotide analogs
EP2697357A4 (en) 2011-04-15 2015-04-22 Univ British Columbia METHOD AND DEVICE FOR SEPARATING PARTICLES
WO2013086331A1 (en) 2011-12-07 2013-06-13 President And Fellows Of Harvard College High efficiency di-nucleotide cyclase
EP2844756A4 (en) 2012-04-30 2016-02-24 Glen N Barber MODULATION OF IMMUNE REACTIONS
AU2013271375B2 (en) * 2012-06-08 2018-03-22 Aduro Biotech, Inc. Compositions and methods for cancer immunotherapy
US9090646B2 (en) 2012-12-05 2015-07-28 Rutgers, The State University Of New Jersey Biotinylated compounds
AU2013358892B2 (en) * 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
KR102255996B1 (ko) 2012-12-19 2021-05-26 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 포유동물 시클릭 디-뉴클레오티드 신호 경로의 약학적 표적화
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
ES2822584T3 (es) * 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
WO2014189806A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
US9642830B2 (en) 2013-10-21 2017-05-09 Drexel University Use of sting agonists to treat hepatitis B virus infection
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US10421971B2 (en) 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
JP6462006B2 (ja) 2014-06-04 2019-01-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingのモジュレーターとしての環式ジヌクレオチド
CN107148424B (zh) 2014-12-16 2021-01-08 凯拉治疗股份公司 用于诱导细胞因子的环状二核苷酸
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA034786B1 (ru) 2015-08-13 2020-03-20 Мерк Шарп И Доум Корп. Циклические динуклеотидные соединения в качестве агонистов sting
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting

Also Published As

Publication number Publication date
HRP20191972T1 (hr) 2020-02-07
AU2014268836B2 (en) 2018-08-02
DOP2015000281A (es) 2016-02-29
JP2016520085A (ja) 2016-07-11
CU20150158A7 (es) 2016-05-30
DK2996473T3 (da) 2019-11-04
KR20160009039A (ko) 2016-01-25
CA2904536A1 (en) 2014-11-27
US20150056224A1 (en) 2015-02-26
SI2996473T1 (sl) 2019-12-31
MX2015015800A (es) 2016-03-15
RS59500B1 (sr) 2019-12-31
BR112015028341A2 (pt) 2017-07-25
HK1219024A1 (zh) 2017-03-24
CY1122274T1 (el) 2020-11-25
ECSP15052938A (es) 2019-03-29
ES2754269T3 (es) 2020-04-16
MY175308A (en) 2020-06-18
PT2996473T (pt) 2019-11-18
WO2014189805A1 (en) 2014-11-27
AP2015008700A0 (en) 2015-08-31
CR20150616A (es) 2016-04-19
GT201500326A (es) 2018-11-27
ES2754269T9 (es) 2020-08-19
US20170333552A1 (en) 2017-11-23
EP2996473A1 (en) 2016-03-23
PL2996473T3 (pl) 2020-06-01
SMT201900635T1 (it) 2020-01-14
CN105228450A (zh) 2016-01-06
PE20160080A1 (es) 2016-02-21
AU2014268836A1 (en) 2015-09-24
WO2014189805A8 (en) 2015-01-22
EP2996473B1 (en) 2019-08-21
CN105228450B (zh) 2019-01-18
HUE046942T2 (hu) 2020-04-28
JP6453855B2 (ja) 2019-01-16
EP3653637A1 (en) 2020-05-20
MX354057B (es) 2018-02-09
SV2015005107A (es) 2018-08-20
HK1222512A1 (en) 2017-07-07
CU24377B1 (es) 2018-12-05
IL242359B (en) 2020-11-30
SA515370123B1 (ar) 2018-02-06
US20200282049A1 (en) 2020-09-10
NI201500162A (es) 2016-01-25
PH12015502438A1 (en) 2016-03-28
PH12015502438B1 (en) 2016-03-28
CL2015002522A1 (es) 2016-12-30
US10653774B2 (en) 2020-05-19
ME03586B (me) 2020-07-20
EP2996473A4 (en) 2017-01-04
SG11201508273RA (en) 2015-12-30
US9724408B2 (en) 2017-08-08

Similar Documents

Publication Publication Date Title
LT2996473T (lt) Kompozicijos ir būdai, skirti aktyvuoti nuo "interferono geno stimuliatoriaus" priklausomą signalinį kelią
LT2970456T (lt) Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui
DK3355884T3 (da) Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
IL246361A0 (en) Antibody conjugates - antidote - trop 2, preparations containing them and their uses
EP3014807A4 (en) INTELLIGENT AMPLIFIER ACTIVATION
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
DK3074027T3 (da) Synergistiske bakteriesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
PL2984076T3 (pl) Estry i etery 2,5-tetrahydrofuranu jako plastyfikatory
FR3002739B1 (fr) Dispositif de protection d'aiguille.
EP2970418A4 (en) STABILIZED EZH2 PEPTIDES
LT3074517T (lt) Kompozicijos ir būdai, skirti sukelti padidintą imuninį atsaką, naudojant raupų viruso vektorius
HUE047484T2 (hu) Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
FR3002740B1 (fr) Dispositif de protection d'aiguille.
FR3002741B1 (fr) Dispositif de protection d'aiguille.
FR3004424B1 (fr) Marchepied amovible d'aeronef, et aeronef
HUE046773T2 (hu) Új 3,4-dihidro-2H-izokinolin-1-on és 2,3-dihidro-izoindol-1-on vegyületek
PL3004076T3 (pl) Nowe związki 3,4-dihydro-2h-izochinolin-1-onowe i 2,3-dihydroizoindol-1-onowe
PT2980096T (pt) Métodos de preparação de 2,3,5 tri-hidroxi-androst-6-ona e utilização do mesmo
EP3048886A4 (en) 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use
FR3041641B1 (fr) 1,4-di-(4-methylthiophenyl)-3-phtaloylazetidine-2-one et ses derives
ES1094985Y (es) Mini-moto infantil
BR302013001894S1 (pt) "configuração aplicada em bebedouro".
IT201600067640A1 (it) Dispositivo per ottimizzare l'aerosolterapia.
TH1501001789A (th) อนุพันธ์ของ 1,2,4-ไตรอะซีน สำหรับการบำบัดของโรคติดเชื้อไวรัส
TH1501006173A (th) องค์ประกอบสารให้ความหวาน, วิธีการสำหรับการผลิตสิ่งเดียวกันนี้ และ การใช้สิ่งนั้น